Treats locally recurrent or metastatic, progressive, radioactive … thyroid cancer (DTC). Sold as Lenvima. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 16, 2026, FDA lists 2 applications for Lenvatinib Mesylate (sold as Lenvima), first approved Feb 13, 2015, with 11 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Lenvima | Part D | $1.14B | +30% | 10,354 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsClear Cell Renal Cell Carcinoma, Ovarian Cancer · Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 | Not yet recruiting | Nov 12, 2026 |
| Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell CarcinomaClear Cell RCC · Jinling Hospital, China | Phase 2 | Recruiting | May 6, 2026 |
| Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerAdvanced Hepatocellular Carcinoma (HCC) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 | Not yet recruiting | Dec 15, 2025 |
| Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric CancerGastric Cancer · First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | Not yet recruiting | Jul 12, 2024 |
| HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerBiliary Tract Cancer · Harbin Medical University | Phase 2 | Not yet recruiting | Apr 29, 2024 |
| Lenvatinib for Advanced Bone and Soft Tissue SarcomaEffectiveness, Sexuality · Henan Cancer Hospital | Phase 2 | Recruiting | Nov 16, 2022 |
| Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyIntrahepatic Cholangiocarcinoma · Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | Recruiting | Apr 22, 2022 |
| Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerOvarian Clear Cell Carcinoma, Gynecologic Cancer · Elizabeth K. Lee MD | Phase 2 | Active, not recruiting | Mar 25, 2022 |
| Feb 13, 2015 | LenvimaNDA 206947 · New molecular entity | Eisai Inc | 24 | Marketed |
| — | LenvatinibANDA 213092 | Sun Pharm Inds Inc | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA